Document is current
Any future updates will be listed below
-
Authors
Yu, Kuan https://orcid.org/0000-0001-6272-9612
Cao, Yifan
Zhang, Zihao
Wang, Leihao
Gu, Yichao
Xu, Tianwei
Zhang, Xiaolei
Guo, Xinxin
Shen, Zhenbin
Qin, Jing https://orcid.org/0000-0001-8833-3165
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03733990 at ClinicalTrials.govnct03733990 at ClinicalTrials.govDocuments that mention this clinical trial
CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer
https://doi.org/10.1136/jitc-2025-013145
709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO
https://doi.org/10.1136/jitc-2022-sitc2022.0709
Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment
https://doi.org/10.1136/jitc-2024-011292
752 Developing biomarkers for bexmarilimab, a novel macrophage-guided immunotherapy, in advanced solid tumors to select patients and confirm mechanism of action
https://doi.org/10.1136/jitc-2023-sitc2023.0752
Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer
https://doi.org/10.1136/jitc-2024-011080
Documents that mention this clinical trial
CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer
https://doi.org/10.1136/jitc-2025-013145
709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO
https://doi.org/10.1136/jitc-2022-sitc2022.0709
Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment
https://doi.org/10.1136/jitc-2024-011292
752 Developing biomarkers for bexmarilimab, a novel macrophage-guided immunotherapy, in advanced solid tumors to select patients and confirm mechanism of action
https://doi.org/10.1136/jitc-2023-sitc2023.0752
Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer
https://doi.org/10.1136/jitc-2024-011080
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82172694)
National Natural Science Foundation of China (82372792)
National Natural Science Foundation of China (82373256)
- License Information
